about
Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.Hereditary ovarian cancer.Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.Endometrial carcinoma: pathology and genetics.Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma.Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.Subcutaneous preconditioning increases invasion and metastatic dissemination in mouse colorectal cancer models.Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis.Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival.STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer.CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced-stage head and neck squamous cell carcinoma.Bottom-Up Instructive Quality Control in the Biofabrication of Smart Protein Materials.Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases.Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.Erratum to: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.Response letter to: Questions about Ki67 staining in luminal breast cancer.Focal adhesion protein expression in human diffuse large B-cell lymphoma.Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4 + colorectal cancer modelsRepression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort?☆Clonality analysis in synchronous or metachronous tumors of the female genital tractMalignant mullerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two casesPrognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinomaPIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parametersSynchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosisMolecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomasLow-density lipoprotein receptor-related protein 1 is associated with proliferation and invasiveness in Her-2/neu and triple-negative breast carcinomas
P50
Q34051933-3592FFEF-DCC7-4004-8424-CA631A852445Q35889941-AA772D23-2B83-4925-B2F7-C6FB778A7F54Q36235943-A1786E21-2034-43A8-8895-C74304D9D5F0Q36557197-AA037D32-58A1-4B7E-A1DD-9B9753464DC5Q36762023-11346967-4F48-4F20-A37F-D28A9061EBB4Q37471694-76517FB5-F0E8-4F66-A507-3C09920E61BBQ37481225-C2914E1B-EC94-4FFA-B5DB-24683FA4B818Q37545395-667B606D-ECA9-4AEC-9A07-DE029D622248Q37621087-4F2FEF38-84F8-43E4-BB12-408F334C06B5Q38597055-7402B457-EFC2-4C88-900A-D3BA1E37957DQ38943652-BB1DF27A-FA90-4DC1-9153-89D7C4664334Q38955569-64C4470C-9001-4CB8-B328-05BB1CE1E833Q39225520-F4589990-ED59-4F3C-8662-307C5E6F181BQ40375971-CC80C1A4-0A37-4D44-8E25-7696AABB1EF7Q40384339-352F3388-7E08-43DF-8E29-4EEBEBBD1C0CQ41112821-4A625106-ADC9-4365-A200-86B4140BD0DDQ43579660-2899F378-0201-455D-8938-E7C4CAC584C4Q46305007-AFA8E653-61CD-4E66-AC9C-FE59BF1815BBQ46716597-A09D4577-547F-4853-8E47-1666E925FF2AQ49690574-5641F91C-773A-4CD3-A33E-525678C561CFQ51119210-7517EB82-23CD-4BF5-ACF8-17CA61FAD94CQ51807138-794D04A6-27D3-4C54-AE7B-7598C284CA6BQ59201780-D3D42F04-CF09-4FB6-A2BF-102A9B00A596Q60221834-9C207882-5B99-4DEC-862B-52FD3401A182Q74310021-B841EFCF-3CB2-499A-A1EA-EF65A7693C8AQ74310041-4EDA03F9-91C4-48BB-9B1B-633CE5B57965Q79828647-C2D7E8E9-2818-4193-BC19-F3868F77ABBDQ80209882-480D95E9-FD0F-44D2-9655-08E2D71E9030Q80380635-679A0725-4B8F-4430-8D5C-F2CD60D2A693Q81314833-BC428CBC-5851-42CA-96DE-91874454FF05Q83877708-121D8D8D-15C1-443B-8F91-F8EFAA04CFC5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alberto Gallardo
@ast
Alberto Gallardo
@en
Alberto Gallardo
@es
Alberto Gallardo
@nl
type
label
Alberto Gallardo
@ast
Alberto Gallardo
@en
Alberto Gallardo
@es
Alberto Gallardo
@nl
prefLabel
Alberto Gallardo
@ast
Alberto Gallardo
@en
Alberto Gallardo
@es
Alberto Gallardo
@nl
P106
P21
P31
P496
0000-0002-2514-2027